Objectives: To describe the natural history of prostate cancer in men who experience a second biochemical recurrence ( BCR ) after salvage radiotherapy ( SRT ) after prostatectomy. Patients and Methods: After undergoing SRT at one of two institutions between 1986 and 2013, 286 patients experienced a second BCR , defined as two rises in prostate‐specific antigen ( PSA ) of ≥0.2 ng/mL above nadir. Event rates for distant metastasis ( DM ) or freedom from DM ( FFDM ), castration‐resistant prostate cancer ( CRPC ), prostate cancer‐specific survival ( PCSS ), and overall survival ( OS ) were estimated using the Kaplan–Meier method. Cox regression was used for comparative analyses. Results: At a median of 6.1 years after second BCR , DM , CRPC , PCSS and OS rates were 41%, 27%, 83% and 73%, respectively. On multivariable analysis, interval to second BCR <1 year (hazard ratio [ HR ] 2.66, 95% confidence interval [ CI ] 1.71–4.14; P < 0.001], Gleason score 8–10 ( HR 1.65, 95% CI 1.07–2.54; P = 0.022), and concurrent ADT during SRT ( HR 1.76, 95% CI 1.08–2.88; P = 0.024) were associated with FFDM , while PCSS was associated with interval to second BCR <1 year ( HR 3.00, 95% CI 1.69–5.32; P < 0.001) and concurrent ADT during SRT ( HR 2.15, CI 1.13–4.08; P = 0.019). These risk factors were used to stratify patients into three groups, with 6‐year FFDM rates of 71%, 59% and 33%, and PCSS rates of 89%, 79%, and 65%, respectively. Conclusion: Following second BCR after SRT , clinical progression is enriched in a subgroup of patients with prostate cancer, while others remain without DM for long intervals. Stratifying patients into risk groups using prognostic factors may aid counselling and future trial design.